LPCN — Lipocine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1535955 ·
Last close
$1.60
Market Cap
$17.72M
52W High
$12.37
52W Low
$1.36
ADV30
3,873,815
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,290,072 | — | -868,525 | -666,192 | 23,196,594 | 2,594,151 | 2,034,446 |
| Jun 2026 | 190,099 | -1,851,290 | -2,842,246 | -2,622,595 | 23,835,361 | 4,979,430 | 2,067,957 |
| Mar 2026 | 119,397 | — | -3,849,464 | -3,671,894 | 25,358,166 | 5,015,608 | 2,527,843 |
| Dec 2025 | 1,145,390 | — | -2,515,801 | -2,370,084 | 17,005,612 | 5,205,842 | 2,528,196 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,190,794
Investing CF
$-6,146,470
Financing CF
$16,272,714
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.86
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-215,690,856
Inventory
—
Receivables
$291,164
ST Investments
$18,287,179
EBIT TTM
$-12,568,551
Pretax Income TTM
$-11,851,205
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,569,460
EBITDA
$-12,509,986
Free Cash Flow
$-6,939,857
Enterprise Value
$-10,395,095
Total Cash
$23,266,608
Total Debt
$257,807
Shares Out
11,073,439
Trailing EPS
$-1.32
Book Value
$2.35
ROE
-60.9%
ROA
-37.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,976,677 | -10,371,379 | -9,627,505 | 17,005,612 | 2,528,196 | 14,477,416 | -9,760,721 |
| Dec 2024 | 11,198,144 | -1,155,035 | 8,352 | 22,510,501 | 1,512,936 | 20,997,565 | -1,221,233 |
| Dec 2023 | -2,850,818 | -17,930,957 | -16,352,082 | 23,001,072 | 2,631,629 | 20,369,443 | -11,865,991 |
| Dec 2022 | 500,000 | -12,119,375 | -10,758,636 | 37,542,922 | 1,907,982 | 35,634,940 | -11,968,819 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,569,460
NetIncome TTM
$-11,851,405
OpCashFlow TTM
—
Assets (Latest)
$23,835,361
Forward EPS
$-1.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $17.90M | $0.04 | — |
| CELU | Celularity Inc | $18.53M | $0.57 | — |
| EDSA | Edesa Biotech, Inc. | $18.90M | $1.96 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $18.96M | $1.90 | — |
| VICP | Vicapsys Life Sciences, Inc. | $16.19M | $0.50 | — |
News headlines (Yahoo Finance, 1h cache)
Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
2026-11-10 13:00 · Yahoo
Lipocine: Q3 Earnings Snapshot
2026-11-05 13:34 · Yahoo
Lipocine Announces Financial Results for the Third Quarter of 2026
2026-11-05 13:00 · Yahoo
Here's Why You Should Add LPCN Stock to Your Portfolio Now
2026-10-08 13:57 · Yahoo
Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market
2026-10-07 14:01 · Yahoo
Lipocine stock surges 30% on Health Canada drug approval
2026-10-07 13:24 · Yahoo
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today
2026-10-07 12:44 · Yahoo
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
2026-10-07 12:00 · Yahoo
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
2026-09-23 16:00 · Yahoo
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.